Brad Margus is a co-founder of Cerevance, a company advancing treatments for brain diseases where he was CEO from inception in 2016 until moving into the Board Chair role in 2023. The company's lead program, CVN424, was effective in a Ph 2 study for Parkinson’s Disease. From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Mr. Margus led the discovery of therapeutics for brain diseases and sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Mr. Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation. Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He founded and leads the A-T Children’s Project, a non-profit that funds research on a rare disease - ataxia telangiectasia or "A-T" - that two of his sons have. He also currently serves on the boards of hC Bioscience, a tRNA company; Tactile Therapeutics, a targeted protein degrader company; and Neurona Therapeutics, a cell therapy company. In addition, he serves as Co-chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH. Mr. Margus obtained his M.B.A. from Harvard Business School.